FDA approves Incivek for hepatitis C

 
 
Share this
 
 

 The current standard of care for patients with chronic hepatitis C infection is peginterferon alfa and ribavirin taken for 48 weeks. Less than 50 percent of patients respond to this therapy.  The safety and effectiveness of Incivek was evaluated in three phase 3 clinical trials with about 2,250 adult patients who were previously untreated, or who had received prior therapy. In all studies patients also received the drug with standard of care. In previously untreated patients, 79 percent of those receiving Incivek experienced a sustained virologic response (i.e. the infection was no longer detected in the blood 24 weeks after stopping treatment) compared to standard treatment alone. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm?sms_ss=email&at_xt=4dda8ce35c28dcaa%2C0